Bisphosphonate generally seems to be safe, but hypocalcemia may occasionally develop in the course of bisphosphonate treatment. Hypocalcemia induced by bisphosphonate is usually mild and asymptomatic, but unrecognized or poorly treated hypocalcemia can lead to life-threatening state. A 78-year-old woman who had a history of hip arthroplasty and intravenous zoledronate treatment for femur neck fracture was presented to emergency department with altered mental status. It turned out that her symptom was due to severe hypocalcemia which was caused by intravenous zoledronate treatment. She also had renal dysfunction. She was treated by intravenous calcium gluconate and calcitriol administration. This case supports the need for evaluation of renal dysfunction, vitamin D deficiency and parathyroid gland dysfunction before bisphosphonate treatment and accurate monitoring of plasma calcium and creatinine levels. In addition, vitamin D and calcium supply during treatment with bisphosphonate is mandatory.
INTRODUCTION
Bisphosphonate is analogues of pyrophosphate compounds and inhibits bone absorption effectively by suppressing osteoclast. In addition, it is utilized in a wide range of treatments including postmenopausal osteoporosis, Paget's disease, cancer-related osteolysis and hypercalcemia.
Although bisphosphonate is known to be safe mostly, side effects such as gastrointestinal side effects, flu-like syndrome, nephrotoxicity, osteonecrosis of the jaw and hypocalcemia can be problematic. [1] Recently, as elderly population increases due to increase of average life-expectancy, bisphosphonate utilization in purpose of prevention and treatment of osteoporotic fracture also tends to increase. Therefore, more attention needs to be paid regarding the side effects. Since the authors experienced a case of severe hypocalcemia after utilizing intravenous bisphosphonate in the treatment of osteoporosis, we would like to report the case with literature review.
CASE
A 78-year-old female patient who had loss of appetite, lethargy, disorientation, and speech disturbance for several days came to our hospital in emergency room due to mental deterioration. About a month before the hospital visit, the patient had femur neck fracture caused by hitting on a table and then received hip arthroplasty under spinal anesthesia.
At the time of the visit, blood pressure, body temperature, pulse rate, and respiratory rate were 120/70 mmHg, 36.5℃, 70 times/minute, and 20 times/minute, respectively, and the patient responded to pains but couldn't communicate. Brain magnetic resonance imaging (MRI) was carried out in order to check the occurrence of cerebrovascular event but acute lesion was not observed. Laboratory test showed the result of leukocyte count 6,530/μL, hemoglobin 11.3 g/dL, platelet count 197,000/μL, blood urea nitrogen 36.9 mg/dL (8-23), serum creatinine 3.67 mg/dL (0.6-1.2), fractional excretion of sodium (FE Na ) 5.9%, serum albumin 3.3 g/dL prolonged, but Trousseau's phenomenon or Chvostek's sign was not exhibited. In the past medical history, no special diseases such as hypertension and diabetes were present and the patient was a non-smoker and a non-drinker. When the patient had femur neck fracture about a month ago, bone mineral density (BMD) was measured utilizing dualenergy X-ray absorptiometry (DXA; Hologic QDR-4500W; Hologic, Inc., Bedford, MA, USA). In result, osteoporosis was considered with T-scores of -3.9 and -3.4 in lumbar spine (L1-4) and hip, respectively (Fig. 1) . Therefore, 5 mg of zoledronate (Aclasta ® ) was injected intravenously for 15 minutes on the day after the surgery and then calcium supplements were continuously being given until visiting the emergency room. In the blood test at the time of injecting zoledronate intravenously, serum creatinine concentration was 2.83 mg/dL and corrected calcium concentration was out-patient clinic after discharging from the hospital, serum creatinine concentration was 3.14 mg/dL and calcium concentration was 7.2 mg/dL (4 weeks after the symptom occurrence) and 9.3 mg/dL (4 months after the symptom occurrence) (Fig. 2) .
DISCUSSION
Bisphosphonates are generally considered as safe drugs but, can be associated with laboratory abnormalities, particularly, elevated serum creatinine levels and hypocalcemia. In the literature, there is well-known direct association between the risk for renal failure and drug infusion time and dose. High-dose (8 mg i.v.) with a short infusion time (5 minutes) is strongly nephrotoxic. In contrast, using the recommended infusion time and dosage (15 minutes and 4 mg i.v., respectively), this drug showed a favorable renal safety profile, comparable with that of placebo. [3, 4] Hypocalcemia is defined as a serum level of total calcium lower than 8.5 mg/dL (2.12 mmol/L). Calcium is mostly (99%) distributed in bone but serum calcium exists in three forms: (1) free or ionized calcium, the physiologically active form (50%); (2) calcium complexed to anions, including bicarbonate, lactate, phosphate, and citrate (10%); and (3) The first case of bisphosphonate-associated symptomatic hypocalcemia was reported in 1987, [6] the case was associated with the use of pamidronate. And then reports of hypocalcemia associated with the use of alendronate [7] and risedronate [8] were followed. In the study performed by Conte et al., [9] hypocalcemia was observed in 17% of patients out of 143 patients who were injected intravenously with pamidronate in order to treat bone metastasis of breast cancer, but all of them were asymptomatic. It is known that zoledronate is 100-1,000 times stronger than alendronate, risedronate, and pamidronate so that the risk of hypocalcemia is considered to be higher as well due to the strong effectiveness.
There are several studies done investigating incidence of zoledronate-induced hypocalcemia. Saad et al. [4] reported that severe hypocalcemia was exhibited in 2% of the patients and Kohno et al. [10] reported high incidence (39%) of hypocalcemia but no severe cases were present.
Lyles et al. [11] reported that only 0.3% patients showed hypocalcemia and considered that this might be due to vitamin D loading before the utilization of zoledronate.
Impaired renal function and vitamin D deficiency are the most significant risk factors in hypocalcemia occurrence. Besides, hypoparathyroidism and hypomagnesemia were significant risk factors as well. [12] Furthermore, simultaneous injection of steroid, pre-existing hypocalcemia, and bone metastasis in more than 3 places had also reported as the risk factors of bisphosphonate-induced hypocalcemia. [13] In case of the patient in our study, PTH level was In spite of concerns regarding the safety of bisphosphonate in CKD, some studies have also mentioned that utilization is too limited [15] because bisphosphonate is effective to decrease the risk of fractures in the patients with CKD and the frequency of side effects is quite low. Also, studies including CKD patients who had severely impaired renal function with 15 mL/min of GFR reported that alendronate [16] and risedronate [17] reduced the risk of fractures effectively without increase of side effects including nephrotoxicity.
Although it is still controversial, given the multiple literatures regarding use of bisphosphonate in CKD patients with reduced BMD, [15, 18, 19] It is difficult to classify renal osteodystrophy based upon clinical or biochemical aspects in general, however, studies reported that low turn-over disease such as adynamic bone disease is rare before CKD stage 5 and the case with less than 150 pg/mL of PTH is useful as a parameter of low turn-over disease (sensitivity 78.1%, specificity 76.2%). [20] Based upon these results, chance to have low turn-over diseases is considered to be low in this patient so bisphosphonate treatment can be considered. However, reduction in BMD of the patient in the present case is highly and calcium and creatinine levels should be measured periodically. If hypocalcemia is suspicious, albumin concentration should be examined and then appropriate treatment should be carried out. In addition, when patients had impaired renal function, GFR is mandatory to calculate and the risk of fractures and presence or absence of renal osteodystrophy is required to be evaluated. Then, whether or not to inject bisphosphonate should be determined carefully.
